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Abstract Aiming at the use of vitamin B12 as a drug
delivery carrier for cytotoxic agents, we have reacted vita-
min B12 with trans-[PtCl(NH3)2(H2O)]
+, [PtCl3(NH3)]
-
and [PtCl4]
2-. These Pt(II) precursors coordinated directly
to the Co(III)-bound cyanide, giving the conjugates [{Co}–
CN–{trans-PtCl(NH3)2}]
+ (5), [{Co}–CN–{trans-PtCl2
(NH3)}] (6), [{Co}–CN–{cis-PtCl2(NH3)}] (7) and [{Co}–
CN–{PtCl3}]
- (8) in good yields. Spectroscopic analyses
for all compounds and X-ray structure elucidation for 5 and
7 confirmed their authenticity and the presence of the
central ‘‘Co–CN–Pt’’ motif. Applicability of these hetero-
dinuclear conjugates depends primarily on serum stability.
Whereas 6 and 8 transmetallated rapidly to bovine serum
albumin proteins, compounds 5 and 7 were reasonably
stable. Around 20% of cyanocobalamin could be detected
after 48 h, while the remaining 80% was still the respective
vitamin B12 conjugates. Release of the platinum complexes
from vitamin B12 is driven by intracellular reduction of
Co(III) to Co(II) to Co(I) and subsequent adenosylation by
the adenosyltransferase CobA. Despite bearing a rather
large metal complex on the b-axial position, the cobamides
in 5 and 7 are recognized by the corrinoid adenosyltrans-
ferase enzyme that catalyzes the formation of the
organometallic C–Co bond present in adenosylcobalamin
after release of the Pt(II) complexes. Thus, vitamin B12 can
potentially be used for delivering metal-containing com-
pounds into cells.
Keywords Cisplatin  Vitamin B12  Targeting 
Adenosyltransferase
Introduction
Cyanocobalamin (aka vitamin B12; hereafter referred to as
B12) is an essential nutrient for most organisms, including
humans. Adenosylcobalamin (AdoCbl, aka coenzyme B12),
the biologically active form of B12, is necessary for the
function of enzymes involved in diverse physiological
processes [1]. In humans, B12 is taken up from the intestine
and is bound to the protein known as intrinsic factor (IF).
The recommended dietary allowance for humans is very
low (1–5 lg) [2], and insufficient intake of B12 leads to
severe diseases such as megaloblastic anemia and neuro-
logical malfunctions [3, 4]. In humans and higher animals,
gastric IF, haptocorrins (HC) and transcobalamins (TC),
bind B12 and promote its entry into the cell via three dis-
tinct cell surface receptors [5]. In plasma, B12 is bound to
transport proteins TCI (HC) and TCII. The complex
between B12 and TCII is taken up by TCII receptor-med-
iated endocytosis. Once inside the cell, the B12–TCII
complex is degraded inside lysosomes to release B12 into
the cytoplasm.
To convert B12 to AdoCbl, the cell needs to reduce the
cobalt ion in the corrin ring from Co(III) to Co(I). The
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latter is a strong nucleophile that attacks the 50C of ATP
forming the unique Co–C bond that tethers the 50-deoxy-
adenosine group (Cob, upper ligand) to the corrin ring, and
releases triphosphate as the byproduct of the reaction [6, 7].
In some microorganisms, the corrinoid adenosylation
pathway comprises three steps. The first step is the
reduction of cob(III)alamin to cob(II)alamin, which is
readily achieved nonenzymatically by dihydroflavins
(FADH2, FMNH2) in the cytosol [8]. The second step of
the pathway is the reduction of cob(II)balamin to
cob(I)alamin by reduced flavodoxin, a nonspecific elec-
tron-transfer protein [7, 9]. The third step is catalyzed by an
ATP:co(I)rrinoid adenosyltransferase enzyme [10]. Ade-
nosyltransferase enzymes have been investigated in several
organisms [11, 12] and are in particular well studied in the
enterobacterium Salmonella enterica. Three evolutionarily
distinct corrinoid adenosyltransferases have been described
in this bacterium, namely, CobA (EC 2.5.1.17), PduO and
EutT [13–15]. Unlike with PduO and EutT, a three-
dimensional structure of the S. enterica CobA enzyme with
substrates bound in the active site has been reported [16].
The nonenzymic reduction of Co(III) to Co(II) releases the
upper axial ligand, usually a cyanide or a water molecule.
Co(III) has been used to directly anchor different types of
bioactive molecules to B12. In particular, fluorescent and
cytotoxic agents have been conjugated via a Co–C bond to
B12 and their biological behavior has been studied in detail
[17–21]. Since the release of cyano group conjugates
would occur preferentially in the cell, these compound–B12
conjugates would be regarded as prodrugs in which the
essential structural features of cobalamin conceal the active
drug attached to it. The indispensable need for AdoCbl in
fast-proliferating sites such as cancerous cells or microbial
infections would allow the use of B12 derivatives as an
agent for site-specific delivery of drugs [18, 22, 23].
In previously reported work, we described conjugates of
B12 of the general composition [{Co}–CN–{M}], where
{M} represents complexes of rhenium, technetium and
platinum bound via the cyano group to B12 [24, 25]. Since
cisplatin and some of its derivatives are well-established
anticancer drugs [26], we decided to use B12 as a vehicle to
deliver these cytostatic drugs. In this paper, we describe
the synthesis and structure of new Pt(II)-complex
adducts of B12. The monoactivated form of cisplatin, cis-
[PtCl(NH3)2(H2O)]
+ (1) bound directly to the cyanide in B12
upon formation of [{Co}–CN–{cis-PtCl(NH3)2}] (2). With
use of the same synthetic approach, the reaction of trans-
[PtCl(NH3)2(H2O)]
+ (3), [PtCl3(NH3)]
- (4) and [PtCl4]
2-
yielded [{Co}–CN–{trans-PtCl(NH3)2}]
+ (5), [{Co}–CN–
{trans-PtCl2(NH3)}] (6), [{Co}–CN–{cis-PtCl2(NH3)}] (7)
and [{Co}–CN–{PtCl3}]
- (8), respectively (Fig. 1).
Release of Pt(II) complexes inside the cell is crucial for
their biological activity. In vitro studies of enzymatic
corrinoid adenosylation by the S. enterica CobA enzyme
confirmed the hypothesis that upper ligands in conjugates
2, 5 and 7 were released upon reduction of Co(III) to Co(II)
and that the resulting corrinoids were converted to AdoCbl.
The Pt(II) complexes (and probably also other ones) were
released during this adenosylation process; hence, B12-
mediated drug uptake and drug release is feasible and B12
can act as a site-specific drug carrier.
Materials and methods
General considerations
All chemicals were purchased from Fluka, Sigma, Strem
and Acros. Chemicals were of reagent grade and used
without further purification. The platinum complex,
K[PtCl3(NH3)] was synthesized according to published
procedures [27]. All reactions were performed under a
nitrogen or argon atmosphere. High-performance liquid
chromatography (HPLC) analyses were performed using a
Merck–Hitachi L-7000 system equipped with a diode-array
UV/vis spectrometer. The following HPLC columns, sol-
vent systems and gradients were used: column 1, Macherey
Nagel C-18ec RP (5-lm particle size, 100-A˚ pore size,
250 mm 9 3 mm); column 2, Merck C-18e RP Super-
sphere1 (100-A˚ pore size, 250 mm 9 4 mm); column 3,
Bio-Sil1 SEC (5-lm particle size, 250-A˚ pore size,
300 mm 9 7.8 mm); solvent system 1, 0.1% AcOH/10%
CH3CN in water, pH 3 (solvent A); MeOH (solvent B);
solvent system 2, 0.1% trifluoroacetic acid in water (sol-
vent A); MeOH (solvent B); solvent system 3, 0.05 M
NaH2PO4, 0.05 M Na2HPO4, 0.01 M NaN3, 0.15 M NaCl,
Fig. 1 Basic structures of vitamin B12 (B12) adducts with Pt(II)
complexes [{Co}–CN–{Pt}]
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pH 6.8 (solvent A); gradient 1: 0–10 min (100% sol-
vent A), 10–30 min (100% solvent A ? 50% solvent A),
30–35 min (50% solvent A ? 0% solvent A); gradient 2,
0–5 min (75% solvent A), 5–30 min (75% sol-
vent A ? 0% solvent A); gradient 3, 0–15 min (100%
solvent A); gradient 4, 0–10 min (100% solvent A), 10–
40 min (100% solvent A ? 80% solvent A). Preparative
HPLC purification was performed using a Varian Prostar
system equipped with two Prostar 215 pumps and a Prostar
320 UV/vis detector, using Macherey Nagel Nucleosil C-
18ec RP columns (7-lm particle size, 100-A˚ pore size,
250 mm 9 20 mm and 250 mm 9 40 mm) and a Waters
Xterra Prep RP8 column (5-lm particle size, 100 mm 9
30 mm). The fractions were collected and concentrated
under a vacuum to eliminate organic solvents and were
finally lyophilized. The purity of the final product was
analyzed by analytical HPLC. If required, additional pre-
parative HPLC separation was performed until 99% purity
was achieved. IR spectra were recorded using a Bio-Rad
FTS-45 spectrometer with the samples in compressed KBr
pills. NMR spectra were recorded with a Varian Gemini
200 or 300 MHz instrument and a Bruker DRX 500 MHz
spectrometer. The chemical shifts are reported relative to
residual solvent protons as a reference. The chemical shifts
of 31P NMR spectra are relative to orthophosphoric acid in
D2O at 0 ppm. The chemical shifts of
195Pt NMR spectra
are relative to K2PtCl4 in D2O at -1,626.4 ppm. Peak
assignments of cobalamin derivatives were determined by
interpolation of the 1H corrrelation spectroscopy and C–H
correlation spectra. Crystallographic data were collected
using a Stoe IPDS diffractometer at -90 C using graph-
ite-monochromated Mo Ka radiation (k = 0.71073 A˚).
Suitable crystals were covered with Paratone N oil,
mounted on top of a glass fiber and immediately transferred
to the diffractometer. Eight thousand reflections distributed
over the whole limiting sphere were selected by the pro-
gram SELECT and used for unit cell parameter refinement
with the program CELL [28]. Data were corrected for
Lorenz and polarization effects as well as for numerical
absorption. Structures were solved with direct methods
using SIR97 [29] and were refined by full-matrix least-
squares methods on F2 with SHELXL-97 [30]. In the case
of 7, both the amine and the chloride group cis to the
cyanide are disordered. Because of the high flexibility in
that part of the structure, they were refined as two disor-
dered pairs on identical positions each. Therefore, the
distances from the platinum to the amine and the chloride
cis to the cyanide cannot be discussed. Crystallographic
data (without structure factors) for the structures reported
in this paper have been deposited with the Cambridge
Crystallographic Data Centre as supplementary publication
nos. CCDC- 655679 and CCDC-655680. Copies of the data
can be obtained free of charge from the CCDC (12 Union
Road, Cambridge CB2 1EZ, UK; Tel: +44-1223-336408;
Fax: +44-1223-336003; e-mail: deposit@ccdc.cam.ac.uk;
Web site: http://www.ccdc.cam.ac.uk). Cyclic voltametry
(CV) was carried out using a Metrohm 757 VA Compu-
trace system with a glassy carbon working electrode, a
glassy carbon counter electrode and a Ag+/AgCl reference
electrode. All compounds were measured at 1 mM con-
centrations in 0.1 M NBu4[PF6] in methanol, the sweep
rate for CV being 0.1 V s-1.
[{Co}–CN–{trans-PtCl(NH3)2}]
+
To a mixture of trans-[PtCl2(NH3)2] (66 mg, 0.220 mmol)
and AgNO3 (38 mg, 0.220 mmol) in the absence of light,
5 mL of H2O was added. The mixture was stirred overnight
and filtrated under N2. A solution of B12 (200 mg,
0.147 mmol) in 15 mL of H2O was added. The reaction
was followed by HPLC measurements (column 1; solvent
system 2; gradient 2; flow rate 0.5 mL min-1), and the
mixture was stirred for 17 h at 45 C in the absence of
light. The solvent was evaporated off and the crude product
purified by preparative HPLC (solvent system 2; gradient
2; flow rate 40 mL min-1) to give 5 as a red powder
(184 mg, 77%). X-ray-quality crystals of 5 were prepared
by vapor diffusion of acetonitrile into an aqueous solution
of 5. 1H NMR (500 MHz, D2O, 20 C) d: 0.38 (s, 3H,
C20), 0.99–1.09 (m, 2H, C410, C600), 1.19 (s, 6H, C46,
Pr3), 1.28 (s, 3H, C36), 1.32 (s, 3H, C54), 1.36 (s, 3H,
C47), 1.77–2.03 (m, 12H, C42, C60, C48, C30, C25, C41),
2.16–2.20 (d, 6H, B10, B11), 2.35–2.74 (m, 19H, C26,
C37, C49, C31, C18, C55, C35, C53, C56), 2.87 (m, 1H,
Pr10), 3.31–3.33 (m, 1H, C13), 3.50–3.71 (m, 9H, C8, Pr1,
R50, NH3–Pt), 3.86–3.88 (m, 1H, R5), 4.00–4.07 (m, 1H,
R4, C19), 4.16–4.23 (m, 3H, C3, Pr2, R2), 4.68 (m, 1H,
R3), 6.04 (s, 1H, C10), 6.30 (s, 1H, R1), 6.43 (s, 1H, B4),
6.98 (s, 1H, B2), 7.22 (s, 1H, B7). 31P NMR (200 MHz,
D2O, 20 C) d: -1.2. 195Pt NMR (107 MHz, D2O, 20 C)
d: -2,350. IR (KBr, cm-1): 2,188. Electrospray ionization
mass spectrometry (ESI–MS): 1,697.6 [M + 2Na +
CH3OH]
+, 1,619.7 [M]+.
6 and 7
To a mixture of K[PtCl3(NH3)] (68 mg, 0.192 mmol) and
B12 (200 mg, 0.147 mmol), 10 mL of MeOH was added.
The reaction was followed by HPLC measurements (col-
umn 2; solvent system 1; gradient 1; flow rate
0.4 mL min-1), and the mixture was stirred for 18 h at
45 C in the absence of light. The solvent was evaporated
off and the crude product purified by preparative HPLC
(Waters Xterra column; solvent system 1; gradient 4; flow
J Biol Inorg Chem (2008) 13:335–347 337
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rate 30 mL min-1). If necessary, a second purification for
each product can be done to eliminate free B12 (RP-C18
column; solvent system 2; gradient 2; flow rate 40 mL
min-1) to give 6 (60 mg, 25%) and 7 (120 mg, 50%) as red
powders. X-ray-quality crystals of 7 were prepared by
recrystallization of the solid by carefully layering acetone
over an aqueous solution of 7 together with NEt4Cl in a
NMR tube.
Spectroscopic data for 6: 1H NMR (500 MHz, CD3OD,
27 C) d: 0.43 (s, 3H, C20), 1.19–1.22 (m, 1H, C41), 1.25
(t, 6H, C46, Pr3), 1.40 (s, 3H, C36), 1.48 (m, 6H, C54,
C47), 1.72–1.82 (m, 4H, C25, C41), 1.82–2.2 (m, 8H, C42,
C600, C48, C30, C410), 2.28 (d, 6H, B10, B11), 2.35–2.94
(m, 22H, C26, C37, C49, C31, C18, C55, C35, C53, C56,
Pr10, C60), 3.31–3.33 (m, 1H, C13), 3.66 (m, 1H, C8), 3.75
(m, 2H, Pr1, R50), 3.92 (s, 1H, R5), 4.10 (m, 1H, R4), 4.23
(m, 2H, R2, C3), 4.29 (d, 1H, C19), 4.36 (m, 1H, Pr2), 4.74
(m, 1H, R3), 6.00 (s, 1H, C10), 6.29 (s, 1H, R1), 6.58 (s,
1H, B4), 7.15 (s, 1H, B2), 7.27 (s, 1H, B7). 31P NMR
(200 MHz, D2O, 20 C) d: -1.19. 195Pt NMR (107 MHz,
D2O, 20 C) d: -2,120. IR (KBr, cm-1): 2,200. ESI–MS:
1,662.8 [M + Na + 2H]+, 1,644.9 [M - NH3 + Na +
H]+, 1,378.7 [M - Pt - 2Cl - NH3 + Na + H]
+.
Spectroscopic data for 7: 1H NMR (500 MHz, CD3OD,
27 C) d: 0.40 (s, 3H, C20), 1.16–1.44 (m, 16H, C46, Pr3,
C410, C420, C47, C54, C36), 1.71–2.30 (m, 10H, C25, C41,
C42, C30, C48, C55, C37), 2.24 (d, 6H, B10, B11), 2.26–
2.85 (m, 22H, Pr1, C26, C60, C56, C550, C370, C31, C49,
C18, C53, C35), 3.20–3.40 (m, 1H, C13), 3.58 (m, 1H, C8),
3.70 (m, 1H, R50), 3.86 (s, 1H, R5), 4.04 (m, 1H, R4), 4.16
(m, 2H, R2, C3), 4.26 (m, 2H, C19, Pr2), 4.66 (m, 1H, R3),
5.95 (s, 1H, C10), 6.24 (s, 1H, R1), 6.55 (s, 1H, B4), 7.11
(s, 1H, B2), 7.24 (s, 1H, B7). 31P NMR (200 MHz, D2O,
20 C) d: -1.19.195Pt NMR (107 MHz, D2O, 20 C) d: -
2,120. IR (KBr, cm-1): 2,193. ESI–MS: 1,661.7 [M +
Na + H]+, 1,378.7 [M - Pt - 2Cl - NH3 + Na + H]
+.
[{Co}–CN–{PtCl3}]
-
To a solution of B12 (200 mg, 0.147 mmol) in 10 mL of
MeOH was added K2[PtCl4] (18 mg, 0.434 mmol). The
reaction was followed by HPLC measurements (column 1;
solvent system 2; gradient 2; flow rate 0.5 mL min-1), and
the mixture was stirred for 10 days at room temperature.
The solvent was evaporated and the crude product purified
by preparative HPLC (solvent system 2; gradient 2; flow
rate 40 mL min-1) to give 8 as a red powder (87 mg, 35%).
1H NMR (500 MHz, D2O, 20 C) d: 0.27 (s, 3H, C20),
0.81–0.87 (m, 2H, C410, C600), 1.08 (s, 3H, C46), 1.11 (br d,
3H, Pr3), 1.23 (s, 3H, C36), 1.31 (s, 3H, C54), 1.34 (s, 3H,
C47), 1.79–1.93 (m, 12H, C42, C60, C48, C30, C25, C41),
2.09 (d, 6H, B10, B11), 2.1–2.2 (m, 2H, C26), 2.3–2.7
(m, 18H, C37, C49, C31, C18, C55, Pr10, C35, C53, C56),
3.16–3.18 (m, 1H, C13), 3.42 (m, 2H, C8, Pr1), 3.61 (d, 1H,
R50), 3.8 (m, 1H, R5), 3.92 (m, 1H, R4), 3.95 (m, 1H, C19),
4.10–4.12 (m, 3H, C3, Pr2, R2), 4.59 (m, 1H, R3), 5.90
(s, 1H, C10), 6.21 (s, 1H, R1), 6.34 (s, 1H, B4), 6.90 (s, 1H,
B2), 7.13 (s, 1H, B7). 31P NMR (200 MHz, D2O, 20 C) d:
-1.03. 195Pt NMR (107 MHz, D2O, 20 C) d: -1,998. IR
(KBr, cm-1): 2,198. ESI–MS: 1,735.4 [M + 2Na +
CH3OH + H]
+, 1,699.4 [M +2Na + CH3OH - Cl]
+,
1,367.5 [M - 2Cl - Pt - Na]+
Binding of B12, 5, 6, 7 and 8 to bovine serum albumin
Bovine serum albumin (BSA; 13 mg, 0.2 lmol) was dis-
solved in phosphate buffer (pH 7.4, 0.1 M, 1 mL). Aliquots
of the freshly dissolved cobalamin derivatives (0.2 lmol)
were added, and the solutions were stirred at room tem-
perature. Binding to the albumin was measured by HPLC
with detection at 360 nm (column 3; solvent system 3;
gradient 3; flow rate 1 mL min-1) as was rate of decom-
position after 48 h (column 1; solvent system 2; gradient 2;
flow rate 0.5 mL min-1). The following amounts of pro-
tein-bound cobalamin were found: B12, no binding after
6 days; 5, 5.64% after 4 h, 11.09% after 24 h, 12.33%
after 48 h, 15.15% after 74 h; 6, 30.11% after 4 h, 59.75
after 24 h, 67.07% after 48 h; 7, 4.73% after 4 h,
11.75% after 24 h, 15.15% after 53 h; 8, 21.55% after 2 h,
30.35% after 4 h, decomposition after 20 h.
Spectroelectrochemical studies
Reduction of cobalamin derivatives from Co(III) to Co(II)
was monitored spectrophotometrically using a Varian Cary
50 spectrometer equipped with a temperature-regulated
cuvette holder. The assay mixture (final volume, 7 mL)
contained cobalamin (100 lM), MgCl2 (800 lM) and
tris(hydroxymethyl)aminomethane (Tris)–Cl buffer (pH 8 at
37 C, 0.2 M). All experiments were done at 37 C. The cell
was equipped with a platinum net working electrode and a
platinum wire counter electrode. Controlled potential cou-
lometry was carried out with an AMEL-549 potentiostat.
Enzymic conversion of B12, aqua-cobalamin, 2, 5 and 7
to AdoCbl
Conversion of cobalamin derivatives to AdoCbl was
monitored spectrophotometrically using a PerkinElmer
Lambda 45 spectrophotometer equipped with a tempera-
ture-regulated cuvette holder. The assay mixtures (final
volume, 1 mL) contained cobalamin derivative (50 lM),
338 J Biol Inorg Chem (2008) 13:335–347
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MnCl2 or MgCl2 (800 lM), Tris–Cl buffer (pH 8 at 37 C,
0.2 M), NADPH (500 lM), Fpr (0.08 mg) and FldA
(0.08 mg [31]). The reaction mixtures were incubated at
37 C in the spectrophotometer. Formation of cob(II)al-
amin was monitored by the decrease in the absorption of
the solution at 525 nm as a function of time. To the pre-
vious assay mixtures ATP (400 lM), and CobA (0.04 mg)
were added. The reaction mixture was incubated at 37 C
in the spectrophotometer. AdoCbl formation was moni-
tored by the increase in the absorption of the solution at
525 nm as a function of time. The products of the corrinoid
adenosylation assays were desalted using a C18 SepPak
cartridge and dried in a SpeedVac concentrator, isolated
and analyzed by HPLC with detection at 525 nm. In vitro
synthesis of adenosylcorrinoids was assessed in vivo by
using strain JE7145 (metE205 ara-9 eutE18::MudI1734
kan+), JE7179 (metE205 ara-9 cobA366::Tn10d(cat+)
eutE18::MudI1734 kan+), JE6583 (metE205 ara-9) or
JE1293 (metE205 ara-9 cobA366::Tn10d(cat+)) as an
indicator strain in biological activity assays. The cells of
the indicator strain grown overnight in 2 mL of nutrient
broth were concentrated by centrifugation and washed with
14.5 mM sterile saline; 0.2 mL of the cell suspension
(approximately 108 cells) was added to 3 mL of molten
soft agar and used to overlay a plate of Vogel–Bonner
minimal medium containing ethanolamine as a carbon and
energy source. The corrinoid standards AdoCbl, B12
and aqua-cobalamin (HOCbl; approximately 150 nM) and
reaction products were spotted (1 lL) onto the overlay and
incubated overnight at 37 C.
Results and discussion
Synthesis and characterization of 5, 6, 7 and 8
The syntheses of compounds 5, 6, 7 and 8 were achieved
via a strategy similar to the one described for compound 2
[25]; the yield and the nature of the products were strongly
dependent on the Pt(II) precursor used (Scheme 1). The
HPLC chromatogram of the reaction between B12 and 1.5
equiv of 3 (prepared from trans-[PtCl2(NH3)2] with 1 equiv
of AgNO3 in water) contained one peak with two different
sets of signals in the 1H NMR spectrum. Previously
reported work showed that the coordination bond between
the benzimidazole base of the nucleotide loop of B12 and
the Co ion of the ring was broken upon binding to a plat-
inum complex [32]. The 195Pt NMR spectrum of the
mixture, however, showed only one 195Pt signal at -
2,350 ppm. In addition, the IR spectrum contained only
one weak characteristic mCN band at 2,188 cm
-1, indicating
that the platinum complex was bound to the cyanide group
in B12. The absence of a mCN band at 2,137 cm
-1,
indicative for B12, further suggested the exclusive coordi-
nation of the platinum complex to cyanide. We propose
that one of the two species identified by the 1H NMR
spectrum is product 5, in which B12 is in the base-on
conformation, whereas in the other species the platinum
complex is coordinated to cyanide in the protonated base-
off conformation. One of the two sets of five signals from
5,6-dimethylbenzimidazole is strongly low-field-shifted
(Fig. 2). In base-off AdoCbl, the imidazole proton from the
benzimidazole appears at 9.16 ppm [33], whereas the res-
onance of the same proton in 5 appears at 9.2 ppm,
implying that this set of signals is from 5 in the base-off
form. Further evidence for the presence of a base-on and
base-off mixture is given by the 31P NMR spectrum, which
showed two signals at -1.2 and -1.6 ppm, consistent with
B12 with an upfield shift of 0.44 ppm upon displacement of
the axial benzimidazole base [34].
pH-dependent base-on/base-off equilibria were reported
for AdoCbl and other corrins [33]. The nature of the b axial
ligand will influence the strength and therefore the release
of the Co–N bond to benzimidazole [34, 35]. Accordingly,
we observed by 1H NMR measurements that the ratio
between the base-on and the base-off products was pH-
dependent. After the synthesis of 5 under acidic conditions
[to prevent formation of hydroxy-bridged Pt(II) com-
plexes], the observed base-off to base-on ratio was about
1:2 in D2O. After addition of base, an almost quantitative
and reversible conversion to one single product occurred.
This result conclusively confirmed the exclusive binding of
Scheme 1 Reagents and conditions for the preparation of conjugates
[{Co}–CN–{Pt}]: i with trans-[PtCl(NH3)2(H2O)]
+ ? 5, MeOH,
17 h at 45 C, 77%; ii with [PtCl3(NH3)]-, MeOH, 18 h at 45 C,
25% ? 6, 50% ? 7; iii with [PtCl4]
2-, MeOH, 10 days at room
temperature, 35% ? 8
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3 to the cyanide in B12, and was in agreement with the
single signal observed in 195Pt NMR measurments.
To estimate the pKa value of benzimidazole, compound 5
was dissolved in 0.25 M sulfuric acid. The base-off to base-
on ratio was about 1:1 (see the supplementary material).
From this information we estimated the pKa value of benz-
imidazole in 5 to be in the range of 0.4, which compares well
with the reported pKa value of about 0.1 for B12 [35].
Following the same synthetic pathway, we directly
reacted 4 with B12 in water without previous precipitation
of one chloride [pathway ii in Scheme 1]. After 4 days of
reaction at room temperature, HPLC analysis revealed two
new compounds. 1H NMR and 31P NMR data implied a
similar product distribution as observed for the formation
of 5, and showed two sets of signals for the desired base-on
and for the corresponding base-off forms. As in the case of
5, the retention times of the base-on and base-off com-
pounds were very similar and they could not be
distinguished or separated from each other by preparative
HPLC. The reaction did not go to completion in water at
room temperature and separation from unreacted B12 by
preparative HPLC was difficult. On the other hand, in
CH3OH or H2O at 45 C, conversion was quantitative after
18 h. HPLC analysis showed two new and clearly sepa-
rated peaks, which could be individually isolated by
preparative HPLC to yield 6 and 7. Compounds 6 and 7
were characterized by positive-ion ESI-MS, with observa-
tion of the characteristic [M + H + Na]+ and [B12 + Na]
+
peaks for 6 and [M + 2H + Na]+, [M - NH3 + H +
Na]+ and [B12 + Na]
+ for 7, respectively (see the supple-
mentary material). According to the trans-effect series,
chloride substitution trans to a further chloride would be
expected, resulting in the preferential formation of com-
pound 7. Indeed, compound 7 was the main product of the
reaction, with about 50% yield. The second product was
the trans isomer 6 (approximately 30% yield) in which the
chloride trans to the single NH3 ligand was replaced by
B12. The IR spectra of 6 and 7 showed mCN stretching
vibrations at 2,200 cm-1 and at 2,193 cm-1, respectively.
The blueshifts as compared with free B12 (2,137 cm
-1) are
characteristic and indicative for bridging cyanides [36].
Furthermore, the 195Pt NMR spectrum gave a broad peak at
-2,120 ppm for both compounds, a region in which signals
of cisplatin- or transplatin-like complexes are usually
observed.
These assumed authenticities could be confirmed by X-
ray structure analysis. Suitable crystals of complex 5 were
grown by H2O/CH3CN vapor diffusion and for complex 7
from H2O/Et4NCl/acetone in NMR tubes by solvent lay-
ering. For 5 and 7, the base-on form was found to
crystallize exclusively. An ORTEP presentation of 5 is
given in Fig. 3 and for 7 in Fig. 4. Crystallographic data
are presented in Table 1 and in the supplementary material.
The ratios of the cell axes are 1.43 and 1.40 for b/a and
1.63 and 1.65 for c/a in the structures of 5 and 7, respec-
tively. These ratios allow a classification of B12 crystal
structures into different clusters. Here, both 5 and 7 belong
to cluster II, the same cluster as recently found for B12
derivatives with metal chelating ligands bound to the corrin
ring [37].
With respect to application of these ‘‘platinated’’ B12
derivatives in drug delivery, the coordinated environment
of compound 7 structurally resembles that of cisplatin.
After reductive cleavage from B12, the released Pt(II)
complex was likely to possess one ammonia and one
cyanide ligand and two chlorides, respectively, in cis ori-
entation. The chlorides can potentially be replaced by, e.g.,
N7 from guanines in DNA to exert a cisplatin-like cyto-
toxic activity. The syntheses of model complexes such as
[PtCl2(CN)(NH3)]
- has not been described yet, but was the
subject of theoretical studies only [38]. Cisplatin-like
activity would probably not be expected for the Pt(II)
complex cleaved from 5 because it possesses only one
chloride. Platinum in conjugate 6 has two chloride ligands
but in trans orientation to each other. Transplatin com-
plexes are in general much less active than cisplatin,
although some exceptions have been reported [39, 40]. The
activity of these monocyano complexes and the influence
on the other ligands bound to platinum remain to be
investigated in more detail with model complexes.
A platinum complex bound to cyanide in B12 with no
ammonia but chloride ligands only completed this series.
Fig. 2 1H NMR (500 MHz, CD3OD, 27 C) spectrum of pure
[{Co}–CN–{trans-PtCl(NH3)2}]
+ (5) (top) and of a mixture of 5
base-on (X) and base-off (O) forms (bottom). For ease of comparison,
only the downfield region from 5 to 9.5 ppm is shown here
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The reaction of [PtCl4]
2- with B12 in methanol was mon-
itored by HPLC. After 10 days of reaction at room
temperature, only small amounts of free B12 (besides some
unidentified side products) were detected. One main signal
indicated the formation of 8, which could be isolated in
35% yield by preparative HPLC. At higher temperatures,
the reaction rate or yield did not increase owing to the
reactivity of [PtCl4]
2-. The amount of side products
increased since 8 started to decompose at elevated tem-
perature. Crystals were obtained by vapor diffusion (H2O/
acetone). X-ray analysis confirmed the authenticity [{Co}–
CN–{PtCl3}]
- of 8 but the overall quality was not good
enough for a detailed discussion.
The electrochemical properties of 5, 6 and 7 are crucial
for the sequence of reactions leading to corrinoid ade-
nosylation [i.e., Co(III) ? Co(II) ? Co(I) ? AdoCbl].
As stated elsewhere, the conjugation of cis-[PtCl2(NH3)2]
to B12 to yield 2 substantially facilitated the reduction of
Co(III) to Co(II) [25]. Whilst B12 exhibited a reduction
wave at E1/2 = -670 mV (vs. Ag
+/AgCl) with about 60%
reversibility, reduction of compound 5 was shifted toward
more positive potentials with E1/2 = -486 mV and
reversibility comparable to B12. Compounds 6 and 7 had
similar potentials at E1/2 = -605 and -584 mV, respec-
tively. The cyclic voltammograms of both compounds 6
and 7 exhibited a high reversibility of 96%. A typical
cyclic voltammogram for B12 and 5 is depicted in Fig. 5.
Obviously, the Co(III) centers in 5, 6 and 7 are easier to
reduce than in B12. Formally, 5 is positively charged at the
platinum center, whereas it is neutral in 6 and 7. The
electron-withdrawing Pt(II) center reduces the electron
donation from cyanide to Co(III) and renders it more
electron poor. Its oxidation potential will consequently
increase as observed. Positively charged conjugate 2 fits in
this sequence with a reduction potential of -515 mV. A
shift of the electrochemical potentials toward more positive
values supports thermodynamically the attempted enzy-
matic reduction in the adenosylation assay.
Stability in BSA solution
For application under physiological conditions, the serum
stability of Pt(II)–B12 conjugates is essential. It is well
known that cisplatin and transplatin bind very rapidly and
essentially irreversible to human serum albumin (HSA)
[41]. The binding of platinum complexes to HSA has been
the subject of many studies and it has been shown that
cysteine, which is abundant in HSA, is the most favorable
site for coordination [42, 43]. Different kinds of interac-
tions of compounds 5, 6, 7 and 8 with serum proteins are
possible. Noncovalent lipophilic binding is usually a fast
and reversible process detectable shortly after incubation.
Fig. 3 ORTEP presentation of 5, selected bond lengths (angstrom)
and angles (degree): Co–C64 1.938(9), C64–N65 1.010(11), Pt1–N65
1.991(9), Pt1–N81 1.856(14), Pt1–N80 2.092(15), Pt1–Cl1 2.236(8),
N81–Pt1–N80 166.0(7), C64–N65–Pt1 171.0(10), N65–C64–Co
175.0(9). Solvent molecules and hydrogen atoms were omitted for
clarity
Fig. 4 ORTEP presentation of [{Co}–CN–{cis-PtCl2(NH3)}] (7),
selected bond lengths (angstrom) and angles (degree): Co–C64
1.885(10), C64–N65 1.151(13), N65–Pt 1.940(10), Cl2–Pt 2.258(8),
N65–C64–Co 178.2(10), C64–N65–Pt 174.5(9). Solvent molecules
and hydrogen atoms were omitted for clarity
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Covalent and therefore essentially irreversible binding
through coordination to platinum by chloride exchange is
slow and evolves with time as observed for cisplatin. Such
interactions can occur with or without cleavage from B12
(transmetallation by binding to the cyano position). The
appearance of free B12 would be indicative for the former
decomposition pathway. It should be noted here that free
B12 has almost no interaction with serum proteins and only
1–2% binds (noncovalently) very rapidly after incubation.
This fraction remains constant over time. Less likely, but to
be considered owing to the increased electrophilicity of
Co(III) in 5, 6, 7 and 8, is the direct attack to Co(III) and
cleavage of a complex such as trans-[Pt(NC)Cl(NH3)2]
from 5. The formation of HOCbl should be observed for
this way of decomposition. Besides potential coordinating
sites from proteins, the tripeptide glutathione (GSH) might
be prone to these processes as well. Present in high con-
centrations in human cells [44], GSH spontaneously forms
glutathionylcobalamin with HOCbl but not with B12 [45].
The availability of unbound B12 conjugates 5, 6, 7 and 8
over time is crucial for efficient cellular uptake and drug
Table 1 Crystal data and
structure refinement for [{Co}–
CN–{trans-PtCl(NH3)2}]
+ (5)
and [{Co}–CN–
{cis-PtCl2(NH3)}] (7)
a R1 = R||Fo| - |Fc||/R||Fo|
b wR2 = {R[w(Fo
2 - Fc
2)2]/
R[w(Fo
2)2]}1/2
5 7
Formula C65H115Cl2CoN17O23PPt C66H108Cl2CoN15O23PPt
Mr 1,858.63 1,835.56
Crystal system Orthorhombic Orthorhombic
Space group P212121 P212121
a (A˚) 15.7056(7) 15.8726(7)
b (A˚) 22.4115(14) 22.0230(13)
c (A˚) 25.5714(11) 26.2190(14)
a () 90 90
b () 90 90
c () 90 90
V (A˚3) 9,000.8(8) 9,165.2(8)
Z 4 4
qcalcd (Mg m
-3) 1.372 1.330
l (mm-1) 1.888 1.852
F (000) 3,848 3,788
Crystal size (mm3) 0.61 9 0.12 9 0.10 0.86 9 0.12 9 0.12
h range () 1.98–25.00 1.76–24.14
Index ranges -18 B h B 18
-26 B k B 26
-30 B l B 30
-18 B h B 17
-25 B k B 25
-30 B l B 30
Reflections collected 65,286 59,906
Independent reflections 15,846 [R(int) = 0.0959] 14,396 [R(int) = 0.0860]
Completeness (%) 99.8 (to h = 25.00) 98.2 (to h = 24.14)
Max/min transmission 0.8337/0.3922 0.8378/0.7363
Data/restraints/parameters 15,846/25/984 14,396/1/964
Goodness of fit on F2 1.004 1.042
Final R indices [I [ 2r(I)]a,b R1 = 0.0984, wR2 = 0.2617 R1 = 0.0892, wR2 = 0.2325
R indices (all data)a,b R1 = 0.1287, wR2 = 0.2840 R1 = 0.1053, wR2 = 0.2434
Absolute structure parameter 0.005(11) 0.033(9)
Largest diffraction peak/hole (e A˚-3) 0.997/-1.712 2.194/-1.127
Fig. 5 Cyclic voltammogram of conjugate 5 (solid lines) and B12
(crossed lines). The concentration of the compounds was 1 mM in
MeOH with 0.1 M Bu4NPF6 as an inert electrolyte (vs. Ag
+/Ag)
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delivery. We investigated the stabilities under these aspects
with two different HPLC systems. Size-exclusion HPLC
quantifies the ratio of BSA bound/unbound B12 and
derivatives. Reversed-phase HPLC accounts for the
authenticity of unbound B12 conjugates 5, 6, 7 and 8. It
should be noted that 5, 6, 7 and 8 were stable in pure water
and no cleavage or decomposition was observed over
several days. The conjugates were incubated in 13 mg
mL-1 BSA solution and phosphate buffer pH 7.4. The
conjugates are more lipophilic than native B12; thus,
increased noncovalent binding to proteins was expected.
The conjugates 5/7 and 6/8, respectively, showed qualita-
tively similar but quantitatively different behavior. Time-
dependent stability studies revealed a rapid association
with BSA due to noncovalent lipophilic interaction during
the first 1–2 h, followed by a smooth increase over the next
48 h. The time dependence of the stability of 7 is given in
Fig. 6.
The latter process represents covalent binding to serum
proteins. For compounds 5 and 7, protein association was
about 9 and 15% after 48 h in comparison with 2% for
native B12. As indicated by the appearance of native B12,
transmetallation to BSA was observed in moderate yield.
After 48 h, about 25% of free B12 with respect to unbound
5 or 7 did form. HOCbl or released platinum complexes
were not found because binding to BSA proteins was rapid
and efficient [46]. Compounds 6 and 8 showed significantly
lower stability. After 24 h, 60% of 6 was bound to the
proteins. This decreased stability correlated well with
previously described instability of transplatin complexes
[47]. Compound 8 decomposed even more rapidly, and to a
high degree owing to its increased substitution liability
compared with that of the other conjugates. Owing to the
instability in BSA solution, 6 and 8 were not included in
the subsequent enzymatic studies. Typical HPLC traces for
compound 5 after 48 h in BSA solution are given in Fig. 7.
The observed behavior for compounds 5 and 7 assessed
their reasonable stabilities in the presence of BSA. The low
concentrations of free B12 indicated transmetallation to a
small extent. Since HOCbl binds very fast to histidine side
chains of BSA proteins, HOCbl, if ever formed, was not
observed for any compound [48].
Enzymatic adenosylation
After TCII receptor-mediated endocytosis, B12 is released
from TCII. To become functionally active, B12 and its
derivatives are either adenosylated in mitochondria or
methylated in the cytoplasm to become the respective
cofactors for methylmalonylcoenzyme A mutase or
methionine synthase. If the platinum complexes were
activated by cleavage from B12, compounds 5 and 7 would
be recognized and processed by the enzymes of the cor-
rinoid adenosylation pathway. The corrinoid adenosylation
system used in this work required the flavin mononucleo-
tide dependent reductase, the electron-transfer protein
flavodoxin (FldA) and the ferredoxin Fpr as reductases for
the steps Co(III) ? Co(II) and Co(II) ? Co(I), respec-
tively. Co(I) was adenosylated by the S. enterica CobA
enzymes using ATP as a cosubstrate via an oxidative
addition. Theoretical calculations based on these sequential
processes were in agreement with corresponding experi-
mental data [49]. It should be emphasized here that in
humans B12 is an unfavorable entry into this process
Fig. 6 Percentage of 7 bound to bovine serum albumin (BSA) versus
time (stars) and formation of B12 from 7 in the presence of BSA
(circles)
Fig. 7 High-performance liquid chromatography (HPLC) traces of 5
in BSA solution monitored at 360 nm after 24 h. a RP-C18 column
for the analysis of B12 compounds, starting material 5 (triangle)
decomposition product free B12 (hash) and cobalamin bound to BSA
(circle). b Size-exclusion HPLC column, all cobalamins bound to
BSA proteins (circle), and free cobalamins (triangle, hash)
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because the cyanide ligand has to be replaced by H2O or
OH- with the help of a b-ligand transferase; the identity of
the latter enzyme is unknown [50, 51]. Only HOCbl would
be converted to AdoCbl. The corrinoid adenosylation assay
is sketched in Scheme 2.
For the purpose of targeted metal complex delivery to,
e.g., cancer cells, the first reductive process Co(III) ?
Co(II) is decisive. Upon reduction of Co(III) to Co(II) the b
axial ligand, in this study the platinum complexes, is
released [52, 53]. After reduction, cob(II)alamin enters the
second reduction Co(II) ? Co(I) and finally adenosyla-
tion. Although only the first process is the basis for drug
delivery, the formation of AdoCbl is an experimental
indication for cleavage of the platinum complexes and has
also been studied. As mentioned earlier, an in vitro
reducing system for the enzymatic conversion of HOCbl to
AdoCbl has been reported previously and we used this
system for assessing the formation of AdoCbl from 5 and 7
[7, 54].
The corrinoid adenosylation process can be subdivided
into three different steps. The respective activities and rates
have been investigated for 5 and 7 and the ‘‘blank’’ com-
pounds B12 and HOCbl. The first two reduction steps can
be mimicked by reducing 5 and 7 chemically with [BH4]
-
(step iv in Scheme 2). Co(I)Cbl has a distinct UV/vis
spectrum with an indicative band at 385 nm. Co(I)Cbl
chemically generated from, e.g., 5 by [BH4]
- reduction
was then catalytically converted by CobA to AdoCbl at a
comparable rate to the one found for the natural substrate
cob(I)alamin generated from HOCbl. The UV/vis spectrum
after [BH4]
- reduction of 5 and the subsequent AdoCbl
spectrum after adenosylation with CobA were identical to
the spectra from authentic samples after full enzymatic
conversion (see below).
On the basis of the measured reduction potentials, it was
not surprising that 5 and 7 were rapidly reduced by [BH4]
-.
More interesting was the question of whether 5 and 7 were
reduced by the FldA–Fpr system. Owing to the character-
istic UV/vis bands of B12 in the different oxidation states,
the stepwise process was monitored spectroscopically.
Typical spectra for the time course of reduction of HOCbl,
5 and 7 from Co(III) to Co(II) in the FldA–Fpr system are
shown in Fig. 8.
This assay clearly showed that compounds 5 and 7 were
reduced and converted to cob(II)alamin by the reductases
despite the presence of a relatively large metal complex
bound to the respective cyanide. It should also be noted
that B12 is a very bad substrate for this reduction process
and reacted at a substantially lower rate than compound 5,
for example. The rate of these reduction processes showed
half-life times for HOCbl to be less than 10 s, 17 min for 5
and 65 min for 7, whereas the reduction of B12 was not
finished even after 24 h. The reduction potential of B12 is
-670 mV. whereas the ones of H2OCbl and 5 are -200
and -486 mV, respectively [52, 53]. The same behavior
was also observed in electrochemical reduction. A spec-
troelectrochemical assay was set up in order to mimic the
in vitro corrinoid adenosylation process. Reduction under
the same conditions (0.2 M Tris buffer, pH 8, 37 C,
800 lM MgCl2 and 50 lM of the corresponding cobala-
min) but now with a continuous potential of -700 mV
revealed a comparable conversion. Typical UV/vis spectra
for the electrochemical reduction of Co(III) to Co(II) for
HOCbl, B12 and 7 are shown in Fig. 9. For the enzymatic
and the electrochemical reduction process, reoxidation of
cob(II)alamin with air gave exclusively HOCbl, implying
the cleavage of the platinum complex together with the
cyanide ligand from cobalt.
When compound 5 was reduced in the FldA–Fpr system
to Co(II) but in the absence of CobA, further reduction to
cob(I)alamin and oxidative addition of ATP to AdoCbl was
not observed. Only addition of CobA and ATP lead to the
reduction of Co(II) to Co(I) in the active site of the CobA
enzyme followed by a nucleophilic attack of C50 of the
Scheme 2 Corrinoid
adenosylation pathway:
electrons for reduction of
cob(III)alamin to cob(I)alamin
are donated by NADPH through
flavodoxin protein. i
Dihydroflavins or Fpr–FADH2,
ii FldA–FMNH+, iii CobA, iv
KBH4
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ribosyl moiety of ATP, resulting in the formation of
AdoCbl and the release of triphosphate. A series of UV/vis
spectra for the adenosylation process with 5 and 7 are
shown in Fig. 10.
As mentioned previously, the Co(III) ? Co(II) reduc-
tion process with the FldA–Fpr system was slower for 5
and 7 than for HOCbl but much faster than for B12. If the
platinum complexes as b axial ligands were released in the
reduced cob(II)alamin, the adenosylation step should occur
at rates comparable to those for HOCbl. Indeed, this was
the case, and about 30 min after addition of CobA and
ATP, AdoCbl formed quantitatively. Although present in
relatively large concentrations (see ‘‘Materials and meth-
ods’’), the Pt(II) complexes released from 5 or 7 did not
affect the rate of these processes, probably owing to the
relatively short time periods of observation.
The final product of the full adenosylation assay
starting from 5 or 7 was isolated by HPLC. To assess its
nature as AdoCbl, its biological activity on the growth of
S. enterica was investigated. Strain JE7179 is a standard
for these tests of biological activity since these cells do
not produce CobA. Therefore, strain JE7179 only grew if
AdoCbl was present in the culture medium. Strong growth
was observed when authentic AdoCbl or the product of
the adenosylation assay of 5 or 7 was provided to the
indicator strain. Strong growth was also observed with
AdoCbl generated in KBH4-dependent adenosylation
assays using 5 or 7 as the substrate. As expected, no
growth was observed with pure B12 or HOCbl or with the
product isolated from reduction to Co(II) with FldA–Fpr
but no subsequent adenosylation. A number of these
growth responses are shown in Fig. 11.
Fig. 8 Reduction of aqua-cobalamin (HOCbl), 5 and 7 using FldA–
Fpr proteins. Spectral changes were associated with the conversion of
cob(III)alamin to cob(II)alamin; UV/vis spectra of 5 and 7 recorded in
10-min intervals. The last spectrum with kmax = 470 nm is that of the
cob(II)alamin solution
Fig. 9 Spectral changes associated with the conversion of cob(III)alamin to cob(II)alamin at E = -700 mV. UV/vis spectra of HOCbl every
10 min; UV/vis spectra of a solution of B12 and 7 every 1 h [measurements of B12 and 7 were stopped before full conversion to Co(II)]
Fig. 10 Spectral changes associated with the conversion of cob(II)
alamin prepared from 5 and 7 in the first reduction step to
adenosylcobalamin (AdoCbl): solution of cob(II)alamin directly after
addition of CobA monitored every 10 min (in the case of 5) or every
5 min (in the case of 7)
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Conclusion
We have synthesized and characterized the four heterodi-
nuclear conjugates 5, 6, 7 and 8 in which B12 acts through
its cyanide group as a ligand to a variety of Pt(II) com-
plexes. To be released, the platinum complexes have to be
cleaved from B12. We showed with an in vitro adenosy-
lation assay from S. enterica that Co(III) is reduced to
Co(II) with the concomitant cleavage of the Pt(II) com-
plexes. This is essential for the use of B12 as a drug
delivery carrier for cisplatin-like compounds such as 7
where the two chloride ligands are reminiscent of cisplatin.
Although only this first step is decisive for the role as a
drug carrier, the B12-based products underwent a further
one-electron reduction Co(II) ? Co(I) and subsequent
adenosylation to AdoCbl in the complete enzymatic assay.
Since the B12 conjugates described here are still converted
by the corresponding enzymes, B12 might serve as a carrier
for cytotoxic substances. The nature of the Pt(II) com-
plexes released, their cytotoxicity and the effect on cancer
cell lines is under investigation.
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